Bio-Rad Laboratories Inc (BIO)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	1,199,100	1,198,710	1,198,380	1,198,000	1,197,700	1,197,270	1,196,940	1,196,740	10,514	10,600	10,779	10,901	12,258	12,241	12,200	12,205	13,579	437,808	437,680	437,600
Total stockholders’ equity	US$ in thousands	8,741,130	8,416,200	8,446,890	9,763,720	9,615,250	8,477,470	8,945,040	10,203,300	13,685,200	15,332,400	11,594,900	10,609,100	9,889,690	8,825,140	7,353,400	6,293,080	5,756,840	5,131,190	5,486,810	4,863,860
Debt-to-equity ratio		0.14	0.14	0.14	0.12	0.12	0.14	0.13	0.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.09	0.08	0.09

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $1,199,100K ÷ $8,741,130K
= 0.14

The debt-to-equity ratio of Bio-Rad Laboratories Inc. has remained relatively stable over the past eight quarters, ranging between 0.12 and 0.14. This ratio indicates that the company has been maintaining a healthy balance between debt and equity in its capital structure.

A debt-to-equity ratio of 0.14 implies that for every dollar of equity, the company has $0.14 in debt. This suggests that Bio-Rad Laboratories relies more on equity financing rather than debt financing to support its operations and growth. A lower debt-to-equity ratio is generally seen as a positive indicator as it signifies lower financial risk and greater financial stability.

The consistency in the debt-to-equity ratio over the quarters reflects the company's cautious approach towards managing its debt levels. By keeping the ratio relatively low and stable, Bio-Rad Laboratories demonstrates financial prudence and a commitment to maintaining a strong financial position.

Overall, based on the trend of the debt-to-equity ratio over the past two years, Bio-Rad Laboratories Inc. appears to be managing its capital structure effectively and maintaining a balanced mix of debt and equity to support its operations and growth strategy.